Oral anti-obesity formulations will be the next growth lever in Danish drugmaker Novo Nordisk's India strategy, following the 2025 launches of its blockbuster diabetes and obesity brands Ozempic and ...

The EU-India trade deal is set to open Europe up to more Indian medicines, deepening reliance on one of its biggest foreign suppliers when the bloc is trying to bolster its own drug production to ...

Novo Nordisk CEO Mike Doustdar has a plan to steer the company through what’s been described as a “show me” year. The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but ...

Nioh 3 is the first game in the series to adopt an open-world approach, where you can explore pretty much wherever you like. There are some constraints to that, as each subregion within the game's ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Senators introduced legislation on Thursday that would ...

Throughout the year, Teva had momentum in innovative medicines, scaling its global generics and biosimilars portfolio. On the brand side, Teva said it continued to showcase strong performance of its ...

Teva Pharmaceutical is one of the leading global generic drug manufacturers. By our estimate, roughly 70% of its total revenue is derived from generics and off-patent branded drugs. Generic drugs in ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

Incyte Corporation is undervalued, with high revenue growth, strong margins, and a 12.7% upside to a $115 target price; rated Buy. INCY's Q3 results beat expectations, driven by Jakafi and Opzelura ...